Here's some of what is coming soon to NeurologyLive® this week.
|Slideshows|December 18, 2015
Interesting Neuro: epilepsy updates & autism risks
Author(s)Samantha J. Peterson
Our Dec. news & research list includes groundbreaking research from AES 2015 as well as a few potential neurodegeneration biomarkers.
Advertisement
We present a selection of interesting neurology articles for the month of December in the following slides. See the slide legends for links to the article summaries.
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
5